Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03092856 · ClinicalTrials.gov registry record · Phase 2

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

A Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by University of Southern California.

Active
Registry status
Phase 2
Development phase
62
Enrollment target
10
Study locations

NCT03092856: Active Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by University of Southern California.

NCT03092856 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 62 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (69% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03092856, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, is active but no longer recruiting, sponsored by University of Southern California.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
62 participants
Enrollment target
10
Study locations

Study Summary

This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.

Primary Outcome

The statistical comparison of PFS in the two treatment arms will be based on the stratified logrank test.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer Metastatic Renal Cell Cancer Recurrent Renal Cell Carcinoma

Interventions

  • OTHER Placebo
  • OTHER Laboratory Biomarker Analysis
  • DRUG Axitinib
  • BIOLOGICAL Anti-OX40 Antibody PF-04518600

Study Locations (10)

California

  • Los Angeles County-USC Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach - Newport Beach
  • University of California Davis Comprehensive Cancer Center - Sacramento

Ohio

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
  • Ohio State University Comprehensive Cancer Center - Columbus

Kansas

  • University of Kansas Cancer Center - Kansas City

New York

  • Weill Cornell Medical College, New York- Presbyterian Hospital - New York

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2017-07-19
Est. Completion 2026-12-31
Phase Phase 2
University of Southern California

617 total trials

What the registry record for NCT03092856 still lists

NCT03092856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (69% lower).

The record links to 4 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT03092856 lists 10 locations in 6 states (California, Ohio, Kansas).

Frequently Asked Questions

What is clinical trial NCT03092856 about?

NCT03092856 is a clinical study titled "Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer". This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms tha...

What is the current status of trial NCT03092856?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2017-07-19. Estimated completion is 2026-12-31.

What conditions does trial NCT03092856 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma.

What interventions are being tested in trial NCT03092856?

The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Axitinib (DRUG), Anti-OX40 Antibody PF-04518600 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03092856?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03092856 being conducted?

This trial has 10 study locations across California, Kansas, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03092856's enrollment target sits among peer trials

62 28th of 45 higher than 18 of 45 other Clear Cell Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03092856, the US trial registry maintained by the National Library of Medicine. NCT03092856 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.